Atorvastatin
Atorvastatin is one of the most widely prescribed statins, with extensive cardiovascular outcome data. PED users use it to control the atherogenic lipid changes of anabolic steroid cycles. It is potent and effective but is more dependent on CYP3A4 metabolism than rosuvastatin, giving it more interaction potential with drugs and supplements that inhibit that enzyme.
01 Overview
Atorvastatin inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and increasing LDL-receptor-mediated clearance of LDL from the blood. It lowers LDL by roughly 40-55% depending on dose and has robust event-reduction evidence across primary and secondary prevention trials.
In the PED context it is used to offset steroid-driven rises in LDL and falls in HDL. A practical consideration is that atorvastatin is metabolised substantially by CYP3A4, so co-use with strong CYP3A4 inhibitors (some antifungals, certain supplements) can raise its levels and myopathy risk. As with all statins, muscle symptoms are the principal tolerability issue, and heavy resistance training complicates interpretation of creatine kinase.
02 Mechanism
Competitive HMG-CoA reductase inhibitor that lowers hepatic cholesterol synthesis and up-regulates LDL receptors; metabolised largely via CYP3A4.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| On-cycle lipid control | 10–40 mg/day | Oral | Titrated to lipid panel during cycles that worsen lipids. |
| Hyperlipidaemia (label) | 10–80 mg/day | Oral | 10-80 mg once daily depending on LDL target and risk. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| LDL reductionPotent, dose-dependent LDL lowering with strong trial support. | -40 to -55% | Clinical | |
| Cardiovascular event reductionReduces cardiovascular events across multiple large trials. | outcome data | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Myalgia / myopathyMuscle aches and, rarely, myopathy or rhabdomyolysis; interaction-sensitive. | Moderate | Common (myalgia) | Clinical | |
| Transaminase elevationUsually mild and reversible liver-enzyme rises. | Mild | Uncommon | Clinical |